Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success...

Psychedelic Capitalism Takes a Trip to Davos

From May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here's why that matters for the psychedelics industry.
MindMed, atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisShutterstock

Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis

,
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
MindMed's Phase 2 LSD Trial Treating Anxiety Was a SuccessShutterstock

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success

,
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Wesana Health May Sell Clinics to Focus Solely on Drug DevelopmentShutterstock

Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis

Wesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and industry at large.
Shutterstock

Elon Musk Excites Psychedelic Industry CEOs with This Tweet

This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
Shutterstock

Why Field Trip Health Is Dividing in Two — and What This Means for Investors

Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.